In HCV-infected patients, HCC screening using biannual AFP, annual abdominal US, or triple phase computed tomography (CT) is more cost effective than engaging in no surveillance, with a cost effectiveness ratio less than $ 50,000 quality-adjusted life years (QALY) [52,53]. Here, AFP is linked to hepatocellular carcinoma.